Radiopharm Theranostics announced its best in class av6 Integrin platform technology has been featured in research journal Cancers. Radiopharm's av6 platform was invented by highly regarded Integrin expert Professor Johannes Notni, with evidence that the av6 Integrin is found in a variety of challenging cancers including pancreatic, head and neck, and certain lung cancers. It may provide outstanding performance in radiolabelling (tracking the movement /breakdown of target molecules) with the Ga-68 radiopharmaceutical tracer, showing promise in the early detection of these cancers using PET imaging. The conclusion to the manuscript indicated that of all integrins, av6 is `arguably the most promising target structure for radiotheranostics', noting its broad clinical scope across oncology as well as fibrotic diseases, which may include COVID-19 related syndromes. While over the past two decades key studies have focused strongly on the subtype v3, the largest number of recent non-v3 integrin targeted first-in-human applications has been reported for radiolabelled compounds homing to av6. The manuscript notes this might lead to a paradigm change and trigger the placement of v3 by av6 `as the most popular integrin in theranostics'.